YC 1

Drug Profile

YC 1

Latest Information Update: 09 Jul 2002

Price : $50

At a glance

  • Originator Yung Shin Pharmaceutical
  • Developer Bayer; Yung Shin Pharmaceutical
  • Class Antiplatelets; Ischaemic heart disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris; Myocardial infarction; Thrombosis

Most Recent Events

  • 11 Jun 1997 A study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections
  • 11 Jun 1997 Preclinical development for Myocardial infarction in Germany (Unknown route)
  • 11 Jun 1997 Preclinical development for Angina pectoris in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top